Castle Biosciences, Inc.

CSTL Healthcare Diagnostics & Research

Castle Biosciences, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $344.2 million, up 3.66% from fiscal 2024. In the quarter to June 2026, revenue grew 20.1%, EPS fell 143.8%, free cash flow fell 43.3% and total debt was flat, each against the same quarter a year earlier. Revenue growth for five consecutive years.

31.96 1.84 −5.44%
Market cap
$1.0B
P/E
0.0×
Fwd P/E
−15.2×
Dividend yield
—
F-score
3/9
Altman Z
6.70
Beneish M
−3.49
Dividend safety
n/a
Dec '25 Dec '24 Dec '23 Dec '22 Dec '21 Dec '20 Dec '19 Dec '18 Dec '17
P/E ratio
0.00 41.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Piotroski F-Score
3 7 5 2 1 4 — — —
Altman Z-Score
6.70 6.74 5.56 7.59 13.21 33.28 6.15 — —
P/S ratio
3.28 2.23 2.68 4.33 11.45 20.29 5.69 1.70 1.70
Altman Z″-Score (non-manufacturers)
6.15 9.07 7.63 10.19 11.93 24.00 7.12 (6.93) —
P/FCF ratio
39.74 20.25 0.00 0.00 0.00 248.40 48.54 0.00 0.00
Beneish M-Score
(3.49) (2.58) (2.37) (2.41) 11.61 (2.38) (2.01) — —
P/Operating CF
41.87 30.38 31.67 (98.92) (387.49) (2,956.01) 65.66 95.59 95.59
P/B ratio
2.39 1.62 1.50 1.49 2.62 3.06 3.47 0.00 0.00
Price to Tangible BV
3.04 2.12 2.15 2.18 3.34 3.06 3.47 0.00 0.00
EV/Sales
2.44 1.38 1.64 2.54 8.04 14.11 4.27 1.96 1.96
EV/EBITDA
0.00 25.44 0.00 0.00 0.00 0.00 23.03 0.00 0.00
EV/Operating CF
13.03 7.05 (63.99) (8.36) (39.83) 89.58 31.55 (16.06) (16.06)
EV/FCF
29.55 12.51 (18.72) (7.39) (33.67) 172.70 36.41 (13.90) (13.90)
Quick Ratio
4.99 6.97 5.90 7.81 13.94 20.24 7.42 2.46 1.12
Current Ratio
5.26 7.29 6.20 8.09 14.21 20.58 7.63 2.69 1.28
Net Debt/EBITDA
46.20 (15.73) 3.98 3.85 8.77 78.35 (7.67) (6.79) (1.78)
Debt/Assets
1.79% 1.95% 0.00% 2.98% 1.75% 0.00% 20.98% 109.35% 0.00%
Debt/Equity
0.02 0.02 0.00 0.03 0.02 0.00 0.30 (0.43) (1.27)
Asset Turnover
0.62 0.67 0.49 0.30 0.21 0.22 0.73 2.03 0.85
Operating CF/Net income
(2.66) 3.56 0.10 0.62 0.61 (0.96) 2.35 1.21 0.80
Capex/Depreciation
(0.98) (3.04) (1.99) (0.59) (1.02) (3.62) (0.41) (0.31) 0.00
Interest Coverage
(497.79) 15.03 (6,179.73) (4,285.59) (40,079.00) (2.48) 1.60 (1.69) (13.01)
ROE
(5.21%) 4.31% (14.54%) (16.56%) (7.56%) (4.11%) 20.95% 19.02% 28.65%
ROA
(4.35%) 3.71% (12.76%) (14.76%) (6.94%) (3.68%) 4.21% (90.72%) (95.00%)
ROIC
(14.72%) 3.13% (28.67%) (29.60%) (27.78%) (70.02%) 40.21% 0.00% 0.00%
Return on Tangible Assets
(6.20%) 5.04% (21.02%) (24.82%) (9.25%) (2.47%) 2.89% (78.67%) (521.83%)
Average Days of Receivables
46.00 56.30 63.61 62.53 67.05 74.34 103.09 193.67 123.46
Research and Development Expense of Revenue
15.06% 15.67% 24.40% 32.77% 31.51% 21.16% 14.24% 21.30% 32.21%
Selling, General and Administrative Expense of Revenue
66.62% 60.24% 81.97% 104.35% 92.19% 76.83% 57.54% 72.29% 110.37%
Intangible Assets out of Total Assets
0.17 0.20 0.26 0.28 0.19 0.00 0.00 0.00 0.00
Share Based Compensation of Revenue
13.33% 15.15% 23.30% 26.50% 23.11% 13.26% 2.41% 1.29% 0.00%
Graham Net Nets
0.22 0.38 0.40 0.41 0.28 0.32 0.28 (1.19) (1.19)
Graham Number
0.00 15.49 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Earnings Yield
(2.16%) 2.44% (9.84%) (11.33%) (2.89%) (0.76%) (3.52%) (24.42%) (24.42%)
Free Cash Flow Yield
2.52% 4.94% (3.27%) (7.93%) (2.08%) 0.40% 2.06% (8.33%) (8.33%)
Revenue per Share
11.88 11.96 8.20 5.26 3.74 3.31 6.04 11.95 0.83
Operating CF per Share
2.22 2.34 (0.21) (1.60) (0.76) 0.52 0.82 (6.45) (0.73)
Capex per Share
(1.24) (1.02) (0.51) (0.21) (0.14) (0.25) (0.11) (0.15) 0.00
Free Cash Flow per Share
0.98 1.32 (0.72) (1.81) (0.89) 0.27 0.71 (6.60) (0.73)
Cash per Share
10.33 10.55 9.07 9.93 13.11 21.65 11.52 2.35 0.07
Shareholders Equity per Share
16.24 16.41 14.60 15.32 16.38 21.96 9.92 (29.68) (0.95)
Interest Debt per Share
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Book value per Share
16.24 16.41 14.60 15.32 16.38 21.96 9.92 (29.68) (0.95)
Free Cash Flow
28.37 36.56 (19.23) (47.09) (22.46) 5.12 6.08 (12.57) (12.23)
Working Capital
292.42 310.76 247.97 256.16 328.86 408.72 101.39 11.39 1.46
Capital Expenditures
(35.98) (28.31) (13.61) (5.44) (3.47) (4.75) (0.94) (0.28) (0.49)
Net Current Asset Value
253.41 284.75 233.56 244.11 302.91 405.96 82.05 (60.84) (18.91)
EV/EBIT
0.00 52.76 0.00 0.00 0.00 0.00 30.20 0.00 0.00
Capex to Sales
0.10 0.09 0.06 0.04 0.04 0.08 0.02 0.01 0.00
Price to Operating Income
0.00 85.38 0.00 0.00 0.00 0.00 40.26 0.00 0.00
Other line items
Depreciation/Fixed assets
0.38 0.18 0.27 0.64 0.36 0.18 1.11 0.58 0.21
Cash ROIC
3.63% 4.81% (3.03%) (7.02%) (3.00%) 0.62% 2.91% 45.57% (220.68%)
Accounts Receivable Turnover
7.28 7.42 7.12 6.72 6.26 4.57 3.88 2.72 1.64
Accounts Payable Turnover
5.55 7.01 6.00 8.80 6.81 4.89 4.41 4.13 3.93
Inventory Turnover
7.73 7.49 7.55 10.67 7.47 5.61 6.90 8.93 8.50
Average Days of Payables
96.15 41.84 83.32 53.95 58.73 79.07 93.12 99.98 80.81
Days of Inventory on Hand
52.69 49.32 64.44 45.38 46.62 83.55 61.77 60.78 22.04
Average Receivables
47.30 44.76 30.89 20.38 15.02 13.70 13.37 8.37 8.37
Average Payables
12.81 8.58 7.50 3.64 2.32 1.98 1.66 1.28 1.28
Average Inventory
9.19 8.04 5.96 3.00 2.12 1.73 1.06 0.59 0.59
Average Assets
554.90 492.29 450.33 454.95 450.95 279.54 71.08 11.20 16.11
Average Common Equity
463.35 423.55 395.21 405.45 413.72 250.40 14.27 (53.44) (53.44)

Fold the line items

Columns are period end dates